May 16th 2024
Data from a meta-analysis of evinacumab trials reveal significant reductions in cholesterol and other lipid markers among patients with dyslipidemia.
Ticagrelor Use Varies Greatly Between Hospitals, Even Without Added Cost Considerations
July 15th 2022After US-based data suggested cost as an inhibiting factor of ticagrelor use in older patients with ACS, an analysis of use in Canada details considerable variation in between-hospital levels of ticargelor, with use ranging from 0% to 83.6% of patients.
Most Stroke Patients Have Undiagnosed Major Risk Factors
June 28th 2022An analysis of data from a single center in Switzerland from a 15-year period details the prevalence of undiagnosed major risk factors among patients admitted with acute ischemic stroke, suggesting 67.7% present with at least 1 undiagnosed risk factor.
Statins Could Slow Progression of Arterial Stiffness in High-Risk Patients
June 20th 2022A retrospective analysis comparing statin users and nonusers details the significant declines in arterial stiffness progression among patients of high atherosclerotic risk based on statin use and adherence in a cohort of more than 5000 patients.
Rivaroxaban Bests Combination Therapy for Total Event, Mortality Risk in Stable CAD with AFib
June 16th 2022A secondary analysis of the AFIRE trial provides further detail on the reduction in event risk and mortality associated with rivaroxaban monotherapy compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease.
Clopidogrel Tops Aspirin for Long-Term Antiplatelet Therapy After PCI in High-Risk Patients
May 20th 2022An analysis of data from the Fuwai PCI registry details the incidence of adverse events and risk of bleeding associated with clopidogrel monotherapy versus aspirin monotherapy 12 months post-PCI in high-risk patients.
Early Aspirin Use Could Lower Mortality, Odds of Stroke in COVID-19
March 24th 2022An analysis of data from more than 110k hospitalized patients with COVID-19 suggests aspirin use on the first day of hospitalization was linked to lower odds for both in-hospital mortality and pulmonary embolism in weighted analyses.
Antiplatelet Therapy Unlikely to Improve Organ Support-Free Days in COVID-19
March 23rd 2022Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.
Hypertriglyceridemia Increases Recurrent Stroke Risk, Despite Statin Use and Well-Controlled LDL-C
March 17th 2022An analysis of data from a prospective stroke registry suggests presence of hypertriglyceridemia was associated with a more than 2-fold increase in risk of MACE among patients with a history of acute stroke or TIA, even with adjustment for baseline LDL-C and statin use.
DOACs Could Lower Bleeding, Hemorrhage Risk vs. Warfarin in Patients with CVT
February 10th 2022An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.
FDA Approves Twice-Yearly Inclisiran (Leqvio) for Lowering Cholesterol in ASCVD, HeFH
December 22nd 2021Announced on December 22, the approval of inclisiran (Leqvio) comes nearly a year after the original PDUFA date. With approval, inclisiran becomes the first and only siRNA therapy approved to lower LDL-C with twice-yearly dosing.
Statin Discontinuation Associated with Excess MACE Events in Older Patients
December 13th 2021Data from an analysis of 67k older Danes suggests statin discontinuation corresponded with 1 excess event per 112 persons per year in a primary prevention cohort and 1 excess event per 77 persons per year in a secondary prevention cohort.
REVERSE-IT: Bentracimab Shows Promise as Fast-Acting Ticagrelor Reversal Agent
November 15th 2021Deepak Bhatt, MD, MPH, discusses the results of the interim analysis of the REVERSE-IT trial presented at AHA 2021, which indicates bentracimab provided immediate and sustained reversal of ticagrelor's antiplatelet effects in patients requiring urgent surgery or experiencing major bleeding.